{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Smallpox&page=3",
    "query": {
      "condition": "Smallpox",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 55,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Smallpox&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Smallpox&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T08:52:08.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00000767",
      "title": "A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "TBC-3B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Smallpox Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 18,
      "start_date": null,
      "completion_date": "1996-07",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000767"
    },
    {
      "nct_id": "NCT00079820",
      "title": "Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "ACAM3000 MVA Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "18 Years to 31 Years"
      },
      "enrollment_count": 110,
      "start_date": "2004-04",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 2,
      "location_summary": "Lenexa, Kansas • Lexington, Kentucky",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079820"
    },
    {
      "nct_id": "NCT01540929",
      "title": "Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 5001,
      "start_date": "2009-09",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 1,
      "location_summary": "Alexandria, Virginia",
      "locations": [
        {
          "city": "Alexandria",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540929"
    },
    {
      "nct_id": "NCT00026611",
      "title": "A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Dryvax vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "32 Years",
        "sex": "ALL",
        "summary": "18 Years to 32 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2001-12",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026611"
    },
    {
      "nct_id": "NCT00038987",
      "title": "Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Wetvax (APSV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "32 Years",
        "sex": "ALL",
        "summary": "18 Years to 32 Years"
      },
      "enrollment_count": 330,
      "start_date": "2002-05",
      "completion_date": "2002-08",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 4,
      "location_summary": "Oakland, California • Iowa City, Iowa • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00038987"
    },
    {
      "nct_id": "NCT01144637",
      "title": "A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "IMVAMUNE®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 4005,
      "start_date": "2013-02",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Los Angeles, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01144637"
    },
    {
      "nct_id": "NCT00042094",
      "title": "Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Cell-Cultured Smallpox Vaccine compared to Dryvax®",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 350,
      "start_date": "2002-03",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00042094"
    },
    {
      "nct_id": "NCT00001043",
      "title": "A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections",
        "HIV Seronegativity"
      ],
      "interventions": [
        {
          "name": "gp160 Vaccine (Immuno-AG)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": "1997-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Seattle, Washington",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001043"
    },
    {
      "nct_id": "NCT00082446",
      "title": "Combination Study With MVA BN and Dryvax",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "Live vaccinia virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA Smallpox Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "32 Years",
        "sex": "ALL",
        "summary": "18 Years to 32 Years"
      },
      "enrollment_count": 91,
      "start_date": "2004-05",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00082446"
    },
    {
      "nct_id": "NCT00053742",
      "title": "Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Modified Vaccinia Virus Ankara TBC-MVA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2003-02",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-22T08:52:08.562Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053742"
    }
  ]
}